Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Therapix Bio Signs MOU with Nanjing BioSciKin for Antibody

publication date: Dec 24, 2014
Therapix Biosciences , an Israeli biotech accelerator, announced a MOU to out-license China rights for its anti-CD3 antibody to Nanjing BioSciKin. As it currently stands, the agreement calls for BioSciKin to be responsible for all China development costs of the antibody plus build a GMP-compliant manufacturing line. BioSciKin will pay $300,000 upfront. Once BioSciKin takes over, Therapix intends to turn its attention to the synthetic cannabinoid drugs being developed by Lara Pharma, a company in which it owns a 25% stake. More details....

Stock Symbols: (TASE: TRPX; OTCQB: THXBY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here